4.7 Article

Neurofilament Levels as Biomarkers in Asymptomatic and Symptomatic Familial Amyotrophic Lateral Sclerosis

期刊

ANNALS OF NEUROLOGY
卷 79, 期 1, 页码 152-158

出版社

WILEY
DOI: 10.1002/ana.24552

关键词

-

资金

  1. Federal Ministry of Education and Research, Germany
  2. MND-Net
  3. Virtual Helmholtz-Institute on RNA Dysmetabolism
  4. Competence Net Neurodegenerative Dementias (project: FTLDc)
  5. EU Joint Programme - Neurodegenerative Disease (JPND) Research Networks for Standardization of Biomarkers (BiomarkAPD, Sophia) and Prefrontals
  6. European Union (NADINE)
  7. foundation of the state of Baden-Wurttemberg
  8. Thierry Latran Foundation
  9. Federal Ministry for Economic Affairs and Energy
  10. BIU

向作者/读者索取更多资源

Neurofilaments are elevated in the cerebrospinal fluid (CSF) and serum of amyotrophic lateral sclerosis (ALS) patients. However, timing of this increase is unknown. To characterize the premanifest disease phase, we performed a cross-sectional study on asymptomatic (n=12) and symptomatic (n=64) ALS mutation carriers and family controls (n=19). Neurofilaments NF-L (neurofilament-light chain) and pNF-H (phosphorylated neurofilament-heavy chain) are normal before symptom onset and increased by at least an order of magnitude at early symptom onset in CSF (pNF-H) or serum and CSF (NF-L). Thus, blood and CSF neurofilament levels are linked to the symptomatic phase of ALS and might serve as objective markers of structural damage to the nervous system.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据